New findings from the WISDOM study (SABCS 2025) suggest that risk-based breast cancer screening is safe and may reduce advanced-stage cancers. However, real-world challenges remain—particularly around biopsy rates and patient adherence.
What’s changing?
Risk assessment is evolving beyond age alone, now incorporating genetics, family history, and imaging data. In WISDOM, risk-based screening resulted in fewer mammograms and fewer advanced cancers, though biopsy rates were similar and adherence impacted outcomes.
Why AI matters?
AI can assess risk directly from mammograms using imaging biomarkers and breast density—no additional tests required. It integrates seamlessly into existing workflows, scales efficiently, and updates over time.
The bottom line:
Risk-based screening shows promise but isn’t ready to replace age-based models yet. AI has the potential to bridge that gap—making personalized screening more practical and scalable.
*Source: This article is adapted from reporting originally published by “The Imaging Wire” and has been contextualized for educational purposes within the medical imaging and digital mammography sector.
- Harmonia™ family of mammography systems.
Medical Scientific is “Innovation and Attention to Detail”
Medical Scientific Ltd., we build new mammography equipment.
Medical Scientific Ltd | 27 Rockland Park Ave | Tappan, NY 10983 US